stockrowiRhythm Holdings, Inc.
IRTC Healthcare Medical Devices
iRhythm Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $747.1 million, up 26.2% from fiscal 2024.
- Revenue
- +14.9%
- EPS
- −462.5%
- Free cash flow
- −157.6%
- Total debt
- +0.48%
Quarter to September 2026, against a year earlier
Follow IRTC
Alert me
iRhythm Holdings, Inc. (IRTC) Return on equity
iRhythm Holdings, Inc.'s return on equity over the twelve months to 30 September 2026 was −25.8%, up 10.8 percentage points from fiscal 2025 (−36.6%). Over the past ten years it has ranged from −76.5% (fiscal 2018) to 461.3% (fiscal 2016); the current reading is higher than 55% of that period. That is below the Medical Devices industry median of −10.4% and in line with the Healthcare sector median of −26.3%.
Return on equity, annual
Embed this chart
Annual newest first
| Period | Return on equity | Change (points) |
|---|---|---|
| FY2025 | −36.6% | 38.70 |
| FY2024 | −75.3% | (20.41) |
| FY2023 | −54.9% | (10.13) |
| FY2022 | −44.7% | (12.09) |
| FY2021 | −32.6% | (14.26) |
| FY2020 | −18.4% | 39.81 |
| FY2019 | −58.2% | 18.32 |
| FY2018 | −76.5% | (41.95) |
| FY2017 | −34.6% | (495.89) |
| FY2016 | 461.3% | 436.30 |
Against its own ten years
Return on equity against peers
| Company | Return on equity |
|---|---|
| TMDX TransMedics Group, Inc. compare | 31.9% |
| LIVN LivaNova PLC compare | 15.5% |
| HAE Haemonetics Corporation compare | 11.9% |
| ITGR Integer Holdings Corporation compare | 5.97% |
| UFPT UFP Technologies, Inc. compare | 0.00% |
| NEOG Neogen Corporation compare | −2.67% |
| TXG 10x Genomics compare | −9.40% |
| AXGN AxoGen, Inc. compare | −10.4% |
| IRTC iRhythm Holdings, Inc. | −25.8% |
| Medical Devices industry median | −10.4% |
| Healthcare sector median | −26.3% |
| Market median | 0.51% |
What Return on equity is
ROE shows how much profit a company earns for its shareholders on the equity they have in the business.
Annual: Net Income Allotted to Shareholders ÷ Average Common Equity; TTM: Net Income Allotted to Shareholders ÷ Average Common Equity (latest quarter)
More on IRTC
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement